Adverse Event Reporting Patterns Evaluated for Methoxy Polyethylene Glycol-Epoetin Beta

A two-stage disproportionality analysis of spontaneous reporting databases has revealed that active comparator selection and reporting context materially alter the interpretation of adverse event signals for methoxy polyethylene glycol-epoetin beta. Conducted using records from the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report database, the pharmacovigilance study assessed reporting patterns, time to onset, and signal specificity for the long-acting erythropoiesis-stimulating agent. While the findings substantiate ongoing postmarketing surveillance for known class-related immunogenicity and severe acute hypersensitivity, structured review of public case fields found no positive evidence specifically implicating the target drug in bone marrow failure or ventricular fibrillation. The authors underscored that because spontaneous adverse event reports cannot estimate incidence or prove causality, rigorous comparative methods are critical to contextualize postmarketing safety observations.

Methoxy polyethylene glycol-epoetin beta is a long-acting erythropoiesis-stimulating agent indicated for the treatment of anemia associated with chronic kidney disease. In clinical practice, evaluating rare immunogenic adverse events, acute hypersensitivity manifestations, and patterns reflecting reduced therapeutic response necessitates structured, long-term postmarketing assessment. To address these safety questions without relying solely on general reporting backgrounds, the investigators designed an analytical strategy utilizing active erythropoiesis-stimulating agent comparators across two major regulatory pharmacovigilance databases. This two-stage framework was established to characterize longitudinal reporting patterns and time to onset while distinguishing drug-specific safety signals from broader adverse events commonly reported across the erythropoiesis-stimulating agent therapeutic class.

The initial screening phase of the investigation evaluated pharmacovigilance records in the FDA Adverse Event Reporting System spanning from the first quarter of 2018 through the first quarter of 2026. Across this multi-year screening period, search strategies identified 6,609 adverse event reports that mentioned methoxy polyethylene glycol-epoetin beta. A primary-suspect comparison restricted to reports designating the medication as the primary suspect drug yielded 145 preferred terms that met defined statistical thresholds for both the reporting odds ratio and the proportional reporting ratio. Among these qualifying preferred terms, 138 met established criteria as three-algorithm consensus signals, providing a broad initial baseline of potential adverse event associations requiring further methodological refinement.

To refine and standardize safety signals for subsequent analytical stages, an exploratory source-restricted rule was applied in parallel to 402 count-qualified preferred terms. This filtering procedure yielded 87 candidate terms, which were subsequently harmonized to 86 Medical Dictionary for Regulatory Activities preferred terms. These 86 harmonized preferred terms were held fixed for subsequent evaluations within lifecycle data from the FDA Adverse Event Reporting System and for comparative analyses involving active erythropoiesis-stimulating agent controls. In addition, eight specific clinical events were prioritized post hoc to undergo corroboration in the Japanese Adverse Drug Event Report database, structured time-to-onset evaluations, and detailed qualitative assessments of individual public case safety fields.

When examined within the lifecycle dataset of the FDA Adverse Event Reporting System, the study cohort encompassed 8,965 primary-suspect reports. Against a broad background comparator comprising all other drugs in the spontaneous reporting database, 38 of the 86 fixed preferred terms met consensus signal criteria. However, when evaluated against strict active comparators consisting of other erythropoiesis-stimulating agents, only 29 of the 86 preferred terms maintained consensus signal status. Crucially, preferred terms for decreased haemoglobin and pure red cell aplasia failed to meet consensus criteria under the active erythropoiesis-stimulating agent comparison in the FDA database, illustrating how active comparator groups filter out background adverse events shared across the pharmacological class.

Targeted investigations of prioritized adverse event categories demonstrated distinct clinical and temporal reporting profiles. Among cases with evaluable temporal data, anaphylactic reaction tended to occur early following administration, though its detected disproportionality varied according to the specific reporting source and observation period examined. Detailed review of 22 individual reports of bone marrow failure revealed that 16 cases had competing clinical explanations or event overlap, four had no identified alternative explanation, and two provided insufficient information for complete clinical assessment. Similarly, among nine submitted reports of ventricular fibrillation, seven occurred within the context of acute alternative explanations or event chains, while the remaining two reports lacked sufficient information to determine contributing factors.

Overall, the investigation demonstrated that comparator selection and reporting context exert a decisive influence on the interpretation of pharmacovigilance safety signals. The study findings reinforce the necessity of sustained postmarketing surveillance for recognized erythropoiesis-stimulating agent immunogenicity and severe acute hypersensitivity reactions. Nevertheless, structured reviews of available public case fields yielded no positive evidence supporting target-drug-specific causality for bone marrow failure or ventricular fibrillation. The authors emphasized that because spontaneous reporting databases are subject to reporting variability, missing clinical details, and inherent reporting biases, such data cannot establish true adverse event incidence or verify direct pharmacological causation in clinical populations.

Subject of Research: Adverse event reporting patterns of methoxy polyethylene glycol-epoetin beta

Article Title: Postmarketing adverse event reporting patterns of methoxy polyethylene glycol-epoetin beta: a two-stage disproportionality analysis of FAERS and JADER with active ESA comparators

Article References: Xu, J., & You, W. (2026). Postmarketing adverse event reporting patterns of methoxy polyethylene glycol-epoetin beta: a two-stage disproportionality analysis of FAERS and JADER with active ESA comparators. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01276-z

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01276-z

Keywords: methoxy polyethylene glycol-epoetin beta, erythropoiesis-stimulating agents, pharmacovigilance, FAERS, JADER, disproportionality analysis, adverse drug events, chronic kidney disease, Postmarketing, adverse, event, reporting